Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashraf Imam

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Anticancer Research|January 18, 2003
LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situArmine Baltayan, Wesley Y Naritoku, Benjapom Chaiwun, et al.
International Journal of Oncology|September 6, 2005
Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpressionAnthony Nguyen, Andrea Rosner, Tatjana Milovanovic, et al.
Canadian Journal of Gastroenterology & Hepatology|April 4, 2019
Parameters Suggesting Spontaneous Passage of Stones from Common Bile Duct: A Retrospective StudyTawfik Khoury, Mohamed Adileh, Ashraf Imam, et al.
Journal of Cancer Research and Clinical Oncology|December 22, 2025
Neoadjuvant SBRT and intraoperative electron radiotherapy in pancreatic cancer resectionGianella Cornejo, Alon Pikarsky, Ayala Hubert, et al.
Anticancer Research|August 28, 2004
LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancerBaisakhi Saha, Ning Zhang, Wesley Y Naritoku, et al.
Pharmaceuticals (Basel, Switzerland)|July 30, 2025
Semaglutide in MASLD Patients: Improved Survival and Liver OutcomesMohamad Suki, Johnny Amer, Yael Milgrom, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the CardiometabolicMohamad Suki, Ashraf Imam, Johnny Amer, et al.
Journal of Nephrology|January 6, 2022
Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-upIddo Z Ben-Dov, Yonatan Oster, Keren Tzukert, et al.
Gut|March 2, 2021
Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesionsDror Kolodkin-Gal, Lior Roitman, Yossi Ovadya, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Anticancer Research|January 18, 2003
LEA.135 expression: identifies low-risk patients with breast ductal carcinoma in situArmine Baltayan, Wesley Y Naritoku, Benjapom Chaiwun, et al.
International Journal of Oncology|September 6, 2005
Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpressionAnthony Nguyen, Andrea Rosner, Tatjana Milovanovic, et al.
Canadian Journal of Gastroenterology & Hepatology|April 4, 2019
Parameters Suggesting Spontaneous Passage of Stones from Common Bile Duct: A Retrospective StudyTawfik Khoury, Mohamed Adileh, Ashraf Imam, et al.
Journal of Cancer Research and Clinical Oncology|December 22, 2025
Neoadjuvant SBRT and intraoperative electron radiotherapy in pancreatic cancer resectionGianella Cornejo, Alon Pikarsky, Ayala Hubert, et al.
Anticancer Research|August 28, 2004
LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancerBaisakhi Saha, Ning Zhang, Wesley Y Naritoku, et al.
Pharmaceuticals (Basel, Switzerland)|July 30, 2025
Semaglutide in MASLD Patients: Improved Survival and Liver OutcomesMohamad Suki, Johnny Amer, Yael Milgrom, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the CardiometabolicMohamad Suki, Ashraf Imam, Johnny Amer, et al.
Journal of Nephrology|January 6, 2022
Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-upIddo Z Ben-Dov, Yonatan Oster, Keren Tzukert, et al.
Gut|March 2, 2021
Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesionsDror Kolodkin-Gal, Lior Roitman, Yossi Ovadya, et al.
Pageof 5